Compare Amgen, Inc. (AMGN) vs BlackBerry Limited (BB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs BlackBerry Limited — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while BlackBerry Limited trades at $10.85 (market cap $6.42B). The key difference: Amgen, Inc. is far larger — about 30.5× BlackBerry Limited's market cap, and Amgen, Inc. pays a 2.77% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| AMGN | BB | |
|---|---|---|
Market Cap | $196.12B | $6.42B |
Sector | Health | Technology |
52-Week High | $388.16 | $12.81 |
52-Week Low | $271.18 | $3.15 |
Enterprise Value | $241.41B | $6.29B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BlackBerry (BB) trades at $10.97, down 4.02% today, with a bullish technical outlook supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights strong QNX growth in automotive and robotics sectors, though valuation metrics remain elevated with P/E at 109.7 and P/S at 11.26.
The outlook is cautiously optimistic as BlackBerry's turnaround gains traction with improved cash flow and QNX momentum. Key risks include execution challenges amid rich valuation and competitive pressures. Analyst consensus leans neutral with 85.7% hold ratings and $10.50 price target, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →
